PHAXIAM Unveils Phagogram Test at International Event
In a significant development for phage therapy, PHAXIAM showcased its IVD Phagogram test during the inaugural "Phagogram Day." This event was organized in cooperation with Phage Canada, bringing together experts from various countries to highlight the urgent need for standardized phagogram methods on a global level, demonstrating the rising interest in phage therapy.
Key Highlights from Phagogram Day
The event marked an important milestone for PHAXIAM as it presented vital phage susceptibility data against various clinical bacterial strains. Experts from Canada, Australia, Germany, Sweden, Belgium, and France shared insights on advancements in phagography and strategies for managing bacterial infections. The collaborative atmosphere emphasized the importance of community in developing effective solutions for combating resistant strains.
Outstanding Results in Phage Performance
PHAXIAM’s phages exhibited exceptional efficacy against significant clinical bacterial strains. The phagogram developed by the company is seen as a powerful tool for healthcare professionals, aiding in the selection of suitable phage-based therapies tailored to individual infections. This development is critical in the fight against antimicrobial resistance (AMR), marking the phagogram as the first in-vitro diagnostic test designed specifically to evaluate phage activity with the relevant CE marking.
Insights Shared by Experts
During the discussions, experts highlighted the rising necessity for reliable diagnostic tools as phage therapy garners global attention. Dr. Rafael Gomes Von Borowski, the Head of Diagnostics & Development at PHAXIAM, expressed his enthusiasm for the collaborative effort, emphasizing the significant progress made in understanding phage susceptibility and the importance of unveiling these promising results. He stated, "As interest in phage therapy grows worldwide, the need for trustworthy diagnostic support is becoming unmistakable. The encouraging results from our phagogram development offer real hope for patients and healthcare providers alike."
Tracking Phage Susceptibility Effectively
PHAXIAM provided compelling data reflecting the susceptibility of major bacterial pathogens to their phages, reinforcing the effectiveness of their treatments. For instance, bacterial infections caused by Staphylococcus aureus showed that 98.7% of strains were susceptible to at least one anti-S. aureus phage, namely PP1493 and PP1815. Meanwhile, for Pseudomonas aeruginosa, there was a 71.3% susceptibility rate against various anti-P. aeruginosa phages including PP1450, PP1777, PP1782, and PP1797.
About PHAXIAM and Its Mission
PHAXIAM is committed to developing groundbreaking biopharmaceutical treatments for combating severe bacterial infections, especially those that are resistant to standard antibiotic therapies. Their approach utilizes phages—naturally occurring viruses that specifically target and kill bacteria—to create an innovative portfolio aimed at treating the top three antibiotic-resistant pathogens: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. With listings on Euronext (ISIN: FR0011471135, ticker: PHXM) and a presence in various key indices, PHAXIAM continues to lead innovations in this vital area of healthcare.
Frequently Asked Questions
What is the Phagogram test by PHAXIAM?
The Phagogram test is an innovative in-vitro diagnostic tool developed by PHAXIAM to assess the susceptibility of clinical bacterial strains to phages, thereby aiding in phage therapy selection.
Who organized the Phagogram Day event?
PHAXIAM organized the Phagogram Day in collaboration with Phage Canada, bringing together international experts in phage therapy.
What are the key benefits of PHAXIAM’s phagogram?
PHAXIAM’s phagogram allows healthcare professionals to make informed decisions when treating resistant bacterial infections, and it plays a crucial role in the monitoring of antimicrobial resistance.
What bacterial strains were tested for susceptibility?
Susceptibility data was presented for major pathogens including Staphylococcus aureus and Pseudomonas aeruginosa, demonstrating high sensitivity to PHAXIAM’s phage candidates.
What is PHAXIAM’s goal in phage therapy?
PHAXIAM aims to create effective phage-based treatments to combat severe resistant bacterial infections, providing innovative solutions to a global health challenge.
